Concepts (155)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Chromatography, High Pressure Liquid | 5 | 2013 | 465 | 0.600 |
Why?
|
| Cytidine Monophosphate | 3 | 2004 | 5 | 0.460 |
Why?
|
| Ribonuclease, Pancreatic | 3 | 2004 | 30 | 0.450 |
Why?
|
| Droperidol | 1 | 2010 | 3 | 0.330 |
Why?
|
| Bromocriptine | 1 | 2010 | 6 | 0.330 |
Why?
|
| Haloperidol | 1 | 2010 | 36 | 0.320 |
Why?
|
| Tandem Mass Spectrometry | 4 | 2013 | 241 | 0.320 |
Why?
|
| Ticlopidine | 3 | 2017 | 17 | 0.320 |
Why?
|
| Thermodynamics | 4 | 2004 | 229 | 0.280 |
Why?
|
| Needles | 2 | 2024 | 10 | 0.260 |
Why?
|
| Administration, Cutaneous | 2 | 2024 | 48 | 0.260 |
Why?
|
| Biological Availability | 3 | 2024 | 116 | 0.260 |
Why?
|
| Ibuprofen | 2 | 2023 | 34 | 0.250 |
Why?
|
| Pharmaceutical Preparations | 2 | 2023 | 94 | 0.230 |
Why?
|
| Cytosine Nucleotides | 1 | 2004 | 1 | 0.220 |
Why?
|
| Drug Delivery Systems | 2 | 2024 | 277 | 0.220 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 77 | 0.220 |
Why?
|
| Cannabidiol | 1 | 2024 | 10 | 0.210 |
Why?
|
| Enzyme Inhibitors | 2 | 2002 | 458 | 0.200 |
Why?
|
| Protons | 1 | 2004 | 94 | 0.200 |
Why?
|
| Skin | 1 | 2023 | 187 | 0.180 |
Why?
|
| Drug Stability | 5 | 2016 | 129 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2023 | 112 | 0.170 |
Why?
|
| Antineoplastic Agents | 3 | 2016 | 1019 | 0.170 |
Why?
|
| Research Design | 1 | 2023 | 385 | 0.170 |
Why?
|
| Rats | 6 | 2024 | 3735 | 0.160 |
Why?
|
| Calorimetry | 3 | 2004 | 20 | 0.150 |
Why?
|
| Animals | 12 | 2024 | 16992 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2017 | 11 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2017 | 11 | 0.130 |
Why?
|
| Noscapine | 1 | 2016 | 17 | 0.120 |
Why?
|
| Molecular Structure | 2 | 2010 | 570 | 0.120 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 159 | 0.110 |
Why?
|
| Buffers | 3 | 2004 | 17 | 0.110 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2024 | 1766 | 0.110 |
Why?
|
| Reference Standards | 2 | 2012 | 55 | 0.100 |
Why?
|
| 2-Aminopurine | 1 | 2013 | 10 | 0.100 |
Why?
|
| Indoles | 2 | 2013 | 187 | 0.100 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2013 | 29 | 0.100 |
Why?
|
| Cattle | 3 | 2004 | 498 | 0.100 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 1 | 2012 | 1 | 0.100 |
Why?
|
| Orchiectomy | 1 | 2013 | 37 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2013 | 103 | 0.100 |
Why?
|
| Platelet Aggregation | 1 | 2013 | 21 | 0.100 |
Why?
|
| Interleukin-2 Receptor beta Subunit | 1 | 2012 | 7 | 0.100 |
Why?
|
| Prostatic Neoplasms | 2 | 2013 | 1092 | 0.100 |
Why?
|
| Quinazolines | 1 | 2013 | 38 | 0.100 |
Why?
|
| Adenosine | 1 | 2013 | 62 | 0.100 |
Why?
|
| Kinetics | 2 | 2004 | 695 | 0.090 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2013 | 58 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 67 | 0.090 |
Why?
|
| Administration, Oral | 4 | 2016 | 260 | 0.090 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2012 | 6 | 0.090 |
Why?
|
| Genes, myc | 1 | 2012 | 31 | 0.090 |
Why?
|
| Camptothecin | 1 | 2012 | 21 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 201 | 0.090 |
Why?
|
| Glucuronides | 1 | 2012 | 25 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 863 | 0.090 |
Why?
|
| Ligands | 2 | 2004 | 388 | 0.090 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 51 | 0.090 |
Why?
|
| Topotecan | 1 | 2011 | 5 | 0.090 |
Why?
|
| Anticarcinogenic Agents | 1 | 2012 | 77 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2013 | 163 | 0.090 |
Why?
|
| Hepatitis, Chronic | 1 | 2011 | 6 | 0.090 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2011 | 13 | 0.090 |
Why?
|
| Hepatitis B virus | 1 | 2011 | 18 | 0.080 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 306 | 0.080 |
Why?
|
| Carrier State | 1 | 2011 | 33 | 0.080 |
Why?
|
| Protein Precursors | 1 | 2011 | 59 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 88 | 0.080 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 291 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2012 | 134 | 0.080 |
Why?
|
| Drug Interactions | 1 | 2010 | 150 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 163 | 0.070 |
Why?
|
| Humans | 14 | 2023 | 43102 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2011 | 224 | 0.070 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 611 | 0.060 |
Why?
|
| Male | 9 | 2024 | 23409 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2013 | 1081 | 0.060 |
Why?
|
| Skin Absorption | 1 | 2024 | 16 | 0.050 |
Why?
|
| Microinjections | 1 | 2024 | 50 | 0.050 |
Why?
|
| Calorimetry, Differential Scanning | 1 | 2004 | 35 | 0.050 |
Why?
|
| Middle Aged | 6 | 2017 | 12222 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2004 | 204 | 0.050 |
Why?
|
| Tablets | 1 | 2023 | 14 | 0.050 |
Why?
|
| Technology, Pharmaceutical | 1 | 2023 | 35 | 0.050 |
Why?
|
| Delayed-Action Preparations | 1 | 2023 | 74 | 0.050 |
Why?
|
| Cations, Monovalent | 1 | 2002 | 7 | 0.050 |
Why?
|
| Cations, Divalent | 1 | 2002 | 25 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2012 | 67 | 0.050 |
Why?
|
| Binding, Competitive | 1 | 2002 | 109 | 0.050 |
Why?
|
| Neoplasms | 1 | 2011 | 1377 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 75 | 0.040 |
Why?
|
| Time Factors | 2 | 2016 | 1857 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2020 | 114 | 0.040 |
Why?
|
| Aged | 4 | 2013 | 8214 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 179 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2013 | 1604 | 0.040 |
Why?
|
| Mice | 3 | 2016 | 6644 | 0.040 |
Why?
|
| Cell Line, Tumor | 2 | 2016 | 2676 | 0.030 |
Why?
|
| Pain | 1 | 2020 | 290 | 0.030 |
Why?
|
| Mannose | 1 | 2016 | 32 | 0.030 |
Why?
|
| Emulsions | 1 | 2016 | 36 | 0.030 |
Why?
|
| Female | 5 | 2017 | 24698 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2016 | 97 | 0.030 |
Why?
|
| Models, Animal | 1 | 2016 | 151 | 0.030 |
Why?
|
| Cisplatin | 1 | 2016 | 98 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 195 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2017 | 423 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 347 | 0.030 |
Why?
|
| Drug Carriers | 1 | 2016 | 174 | 0.030 |
Why?
|
| Tubercidin | 1 | 2013 | 4 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2013 | 45 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 307 | 0.020 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2012 | 8 | 0.020 |
Why?
|
| Interleukin-15 | 1 | 2012 | 13 | 0.020 |
Why?
|
| Macaca fascicularis | 1 | 2012 | 65 | 0.020 |
Why?
|
| Heterozygote | 1 | 2013 | 110 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 317 | 0.020 |
Why?
|
| Adult | 3 | 2017 | 13872 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 945 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2012 | 31 | 0.020 |
Why?
|
| Permeability | 1 | 2012 | 67 | 0.020 |
Why?
|
| Cell Division | 1 | 2012 | 311 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2012 | 64 | 0.020 |
Why?
|
| Calibration | 1 | 2012 | 63 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2013 | 237 | 0.020 |
Why?
|
| Solubility | 1 | 2012 | 139 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2012 | 118 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2012 | 206 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 455 | 0.020 |
Why?
|
| Regional Blood Flow | 1 | 2011 | 53 | 0.020 |
Why?
|
| Swine | 1 | 2012 | 212 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 153 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 374 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2012 | 147 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2011 | 93 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 575 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 800 | 0.020 |
Why?
|
| Nanoparticles | 1 | 2016 | 460 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2013 | 1067 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 1596 | 0.020 |
Why?
|
| Prognosis | 1 | 2013 | 861 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 1124 | 0.020 |
Why?
|
| DNA | 1 | 2013 | 592 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2013 | 587 | 0.020 |
Why?
|
| Liver | 1 | 2012 | 511 | 0.020 |
Why?
|
| Models, Biological | 1 | 2012 | 712 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2011 | 760 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2012 | 1271 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 2853 | 0.010 |
Why?
|
| Risk Factors | 1 | 2012 | 3994 | 0.010 |
Why?
|
| Metals | 1 | 2002 | 114 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 671 | 0.010 |
Why?
|
| Young Adult | 1 | 2011 | 5080 | 0.010 |
Why?
|